MRA(Tocilizumab)

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Systemic Juvenile Idiopathic Arthritis

Conditions

Systemic Juvenile Idiopathic Arthritis

Trial Timeline

Nov 1, 2004 → Oct 1, 2005

NCT ID

NCT00144664

About MRA(Tocilizumab)

MRA(Tocilizumab) is a phase 3 stage product being developed by Chugai Pharmaceutical for Systemic Juvenile Idiopathic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00144664. Target conditions include Systemic Juvenile Idiopathic Arthritis.

What happened to similar drugs?

10 of 20 similar drugs in Systemic Juvenile Idiopathic Arthritis were approved

Approved (10) Terminated (4) Active (7)

✅Baricitinib + CyclophosphamideEli LillyApproved

✅Rosuvastatin + SimvastatinAstraZenecaApproved

✅AnifrolumabAstraZenecaApproved

✅EfalizumabMerckApproved

✅AmbrisentanGilead SciencesApproved

✅BMS-986165Bristol Myers SquibbApproved

✅versus hydroxychloroquineSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00380601	Phase 3	Completed	May 1, 2006	Feb 1, 2009	Rheumatoid Arthritis
NCT00144586	Phase 3	Completed	Mar 1, 2005	Jun 1, 2009	Rheumatoid Arthritis
NCT00144625	Phase 3	Completed	Feb 1, 2005	Jun 1, 2009	Polyarticular Juvenile Idiopathic Arthritis
NCT00144560	Pre-clinical	Completed	Feb 1, 2005	Aug 1, 2005	Rheumatoid Arthritis
NCT00144573	Pre-clinical	Completed	Jan 1, 2005	Oct 1, 2005	Rheumatoid Arthritis
NCT00144664	Phase 3	Completed	Nov 1, 2004	Oct 1, 2005	Systemic Juvenile Idiopathic Arthritis
NCT00144612	Phase 3	Completed	Jul 1, 2004	Jun 1, 2009	Systemic Juvenile Idiopathic Arthritis
NCT00144547	Phase 3	Completed	Apr 1, 2004	Jun 1, 2009	Rheumatoid Arthritis
NCT00144651	Phase 2	Completed	Aug 1, 2001	Jun 1, 2009	Rheumatoid Arthritis

Competing Products

20 competing products in Systemic Juvenile Idiopathic Arthritis

See all competitors

Product	Company	Stage	Hype Score
Tabalumab Auto-Injector + Tabalumab Prefilled Syringe	Eli Lilly	Phase 3	32
Baricitinib + Placebo	Eli Lilly	Phase 2	35
MRA(Tocilizumab) + placebo	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
DS-7011a + Placebo	Daiichi Sankyo	Phase 1	29
DS-7011a + Placebo	Daiichi Sankyo	Phase 1/2	32
Bocidelpar + Placebo	Astellas Pharma	Phase 1	21
Parenteral micafungin application + Other parenteral antifungal drugs	Astellas Pharma	Pre-clinical	26
Micafungin	Astellas Pharma	Phase 2	35
E6742	Eisai	Phase 1/2	32
KHK4827	Kyowa Kirin	Phase 1	29
KHK4827 + Placebo	Kyowa Kirin	Phase 3	40
Baricitinib + Placebo	Eli Lilly	Phase 3	40
Baricitinib + Cyclophosphamide	Eli Lilly	Approved	47
Baricitinib + Placebo	Eli Lilly	Phase 3	32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care	Eli Lilly	Phase 3	40
LY3361237 + Placebo	Eli Lilly	Phase 2	27
LY2127399 + Placebo	Eli Lilly	Phase 3	32
LY3361237 + Placebo	Eli Lilly	Phase 1	29
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks	Eli Lilly	Phase 3	40